Aerovate Therapeutics (AVTE) Competitors $2.63 -0.06 (-2.23%) (As of 04:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVTE vs. IMMP, ITOS, ATYR, TNYA, ADCT, CCCC, ELDN, RZLT, BNTC, and URGNShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Immutep (IMMP), iTeos Therapeutics (ITOS), Atyr PHARMA (ATYR), Tenaya Therapeutics (TNYA), ADC Therapeutics (ADCT), C4 Therapeutics (CCCC), Eledon Pharmaceuticals (ELDN), Rezolute (RZLT), Benitec Biopharma (BNTC), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Immutep iTeos Therapeutics Atyr PHARMA Tenaya Therapeutics ADC Therapeutics C4 Therapeutics Eledon Pharmaceuticals Rezolute Benitec Biopharma UroGen Pharma Aerovate Therapeutics (NASDAQ:AVTE) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Do insiders and institutionals believe in AVTE or IMMP? 2.3% of Immutep shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend AVTE or IMMP? Aerovate Therapeutics presently has a consensus price target of $2.25, indicating a potential downside of 14.45%. Immutep has a consensus price target of $8.50, indicating a potential upside of 300.94%. Given Immutep's stronger consensus rating and higher possible upside, analysts clearly believe Immutep is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, AVTE or IMMP? Aerovate Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Is AVTE or IMMP more profitable? Immutep's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Immutep N/A N/A N/A Does the MarketBeat Community believe in AVTE or IMMP? Immutep received 293 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformAerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% ImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has stronger valuation and earnings, AVTE or IMMP? Immutep has higher revenue and earnings than Aerovate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.88Immutep$5.14M60.00-$28.01MN/AN/A Does the media refer more to AVTE or IMMP? In the previous week, Immutep had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Immutep and 0 mentions for Aerovate Therapeutics. Immutep's average media sentiment score of 0.30 beat Aerovate Therapeutics' score of 0.00 indicating that Immutep is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Immutep Neutral SummaryImmutep beats Aerovate Therapeutics on 13 of the 14 factors compared between the two stocks. Ad Porter & CompanyTwo halves of the same soul…What I’m about to tell you is a story that is so ironic and unexpected that it’s almost inconceivable. It’s the story of two men, who live 2,400 miles away from one another. One is in California. The other, Ohio. And now, for the first time, the lives of these two men have intersected on a single investment.Click here to see what is happening Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.69M$6.99B$5.29B$9.16BDividend YieldN/A8.09%5.63%4.06%P/E Ratio-0.9010.19132.5617.59Price / SalesN/A341.551,213.90164.82Price / CashN/A22.4935.0335.62Price / Book0.685.454.834.97Net Income-$75.52M$150.76M$117.71M$224.59M7 Day Performance2.67%0.76%0.95%1.32%1 Month Performance-1.10%-4.07%-0.29%6.29%1 Year Performance-84.21%24.51%33.77%29.33% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics0.4422 of 5 stars$2.63-2.2%$2.25-14.4%-84.2%$75.94MN/A-0.8851IMMPImmutep1.1822 of 5 stars$2.14+2.4%$8.50+297.2%+4.8%$311.28M$5.14M0.002,021Positive NewsITOSiTeos Therapeutics3.7064 of 5 stars$8.38+0.7%$31.50+275.9%-14.3%$306.16M$35M-2.6490Positive NewsATYRAtyr PHARMA2.5853 of 5 stars$3.62+7.7%$19.25+431.8%N/A$303.86M$350,000.00-3.8756Analyst ForecastNews CoverageTNYATenaya Therapeutics3.9277 of 5 stars$3.83+7.0%$17.33+352.6%+89.9%$303.41MN/A-2.71110Gap UpHigh Trading VolumeADCTADC Therapeutics2.9258 of 5 stars$3.09-1.3%$8.25+167.0%+214.2%$298.77M$69.56M0.00310High Trading VolumeCCCCC4 Therapeutics1.3866 of 5 stars$4.21-4.8%$10.00+137.5%+222.3%$297.18M$20.76M-2.60150News CoverageGap UpELDNEledon Pharmaceuticals2.4293 of 5 stars$4.95+7.6%$16.00+223.2%+281.9%$295.71MN/A-2.3310Gap UpHigh Trading VolumeRZLTRezolute3.258 of 5 stars$5.08-1.9%$24.13+374.9%+483.7%$294.35MN/A-4.0540BNTCBenitec Biopharma3.1974 of 5 stars$12.44+10.8%$22.60+81.7%+272.5%$288.86M$80,000.000.0020News CoverageURGNUroGen Pharma4.2389 of 5 stars$12.21-0.7%$43.70+257.9%-14.7%$286.32M$82.71M-3.90200Positive News Related Companies and Tools Related Companies Immutep Competitors iTeos Therapeutics Competitors Atyr PHARMA Competitors Tenaya Therapeutics Competitors ADC Therapeutics Competitors C4 Therapeutics Competitors Eledon Pharmaceuticals Competitors Rezolute Competitors Benitec Biopharma Competitors UroGen Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTE) was last updated on 12/10/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored50-year Wall Street legend names #1 stock of 2025The S&P has blown through more than 50 all-time highs since the year began... And a 50-year Wall Street le...Chaikin Analytics | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
